Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 781

Sort by

Sort Order Select

Journal Articles

A master erythroid regulator gets its own GPS

Lily Jun-shen Huang, James J. Bieker

Blood (2020) 135 (25): 2209–2210.

https://doi.org/10.1182/blood.2020005882

Published: 2020

Journal Articles

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

Yun Dai, MD, Yue Sun, MS, Shaji K. Kumar, MD, Wei Wu, MD, Fengyan Jin, MD PhD

Blood (2019) 134 (Supplement_1): 687.

https://doi.org/10.1182/blood-2019-132051

Published: 2019

Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD

Blood (2019) 134 (Supplement_1): 123.

https://doi.org/10.1182/blood-2019-128096

Published: 2019

Journal Articles

Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias

Anthony K. N. Chan, PhD, Christopher D. Delaney, Lu Yang, PhD, Wen-Han Chang, PhD, Kazuya Miyashita, PhD, Qiao Liu, MD, Sheela Pangeni Pokharel, MSc, Scott A. Armstrong, MD PhD, Chun-Wei David Chen, PhD

Blood (2019) 134 (Supplement_1): 530.

https://doi.org/10.1182/blood-2019-131467

Published: 2019

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

Theodore Braun, MD PhD, Cody Coblentz, Sarah A Carratt, PhD BS, Mariam Okhovat, PhD, Amy Foley, MEng., Zachary Schonrock, BS, Kimberly Nevonen, Rhonda E. Ries, MA, Shannon K. McWeeney, PhD, Claus Nerlov, PhD, Soheil Meshinchi, MD PhD, Lucia Carbone, PhD, Brian J. Druker, Julia E. Maxson, PhD

Blood (2019) 134 (Supplement_1): 543.

https://doi.org/10.1182/blood-2019-124773

Published: 2019

Journal Articles

Super-Enhancer Profiling Identifies Novel Oncogenes and Therapeutic Targets in Multiple Myeloma

Jianbiao Zhou, MD PhD, Yunlu Jia, MD, Tze King Tan, PhD, Tae-Hoon Chung, PhD, Takaomi Sanda, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2019) 134 (Supplement_1): 362.

https://doi.org/10.1182/blood-2019-124252

Published: 2019

Journal Articles

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

Blood (2019) 134 (Supplement_1): 109.

https://doi.org/10.1182/blood-2019-122483

Published: 2019

Journal Articles

Terminal Erythroid Maturation Is Associated with Dynamic Changes in the Abundance of Histone Marks Associated with Active Transcription Elongation and RNA Polymerase II Pausing

Zachary C. Murphy, PhD, Tyler A Couch, BS, Jacquelyn Lillis, MS, Michael Getman, MS, Kimberly Lezon-Geyda, PhD, Vincent P Schulz, PhD, Mohandas Narla, DSc, Patrick G. Gallagher, MD, Laurie A. Steiner, MD

Blood (2019) 134 (Supplement_1): 154.

https://doi.org/10.1182/blood-2019-129561

Published: 2019

Journal Articles

Prevention of Bleeding-Induced Vascular Abnormalities in the Hemophilic Mouse Joint By Increasing TAFI Levels or Inhibiting uPA Activity

Tine Wyseure, PhD, Niels Behrendt, Annette von Drygalski, MD PharmD, Laurent O Mosnier

Blood (2019) 134 (Supplement_1): 158.

https://doi.org/10.1182/blood-2019-128723

Published: 2019

Journal Articles

Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide

Sinto Chirackal, PhD, Esteban Braggio, PhD, Rahman Atiqur, PhD, Gregory J Ahmann, BS, Yuan Xiao Zhu, PhD, A. Keith Stewart, MB, ChB, Marta Chesi, PhD, P. Leif Bergsagel, MD, Rafael Fonseca, MD

Blood (2019) 134 (Supplement_1): 4410.

https://doi.org/10.1182/blood-2019-124967

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 5085.

https://doi.org/10.1182/blood-2019-123811

Published: 2019

Journal Articles

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Lei Guo, PhD, Jia Li, PhD, Hongxiang Zeng, PhD, Anna Guzman, Tingting Li, MD, Minjung Lee, MS, Yubin Zhou, PhD, Clifford Stephan, Peter J.A Davies, Margaret Goodell, PhD, Deqiang Sun, PhD, Mark A. Dawson, PhD MBBS, Yun Huang, PhD

Blood (2019) 134 (Supplement_1): 5053.

https://doi.org/10.1182/blood-2019-130586

Published: 2019

Journal Articles

LSD1 Inhibitor 4SC-202 Inducing Apoptosis in Myelodysplastic Syndrome Cells Via NF-κb-HO-1 Pathway

Weili Wang, MD, Zhaoyuan Zhang, Xingyi Kuang, PhD, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 5415.

https://doi.org/10.1182/blood-2019-130486

Published: 2019

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Giovanni Caocci, MD, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa

Blood (2019) 134 (Supplement_1): 4144.

https://doi.org/10.1182/blood-2019-124323

Published: 2019

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL

Valeriya Dimitrova, Huiyoung Yun, PhD, Sayalee Potdar, Alexandria Nicole Van Scoyk, BS, Shruti Bhatt, PhD, Praveen Anand, PhD, Monica S. Nair, Jake A. Kloeber, Antonis Kokkalis, PhD MSc, Julia Frede, PhD MPhil, Johannes M. Waldschmidt, MD, Anthony G. Letai, MD PhD, David M. Weinstock, MD, Jon C. Aster, MD PhD, Jens G. Lohr, MD PhD, Birgit Knoechel, MD PhD

Blood (2019) 134 (Supplement_1): 3948.

https://doi.org/10.1182/blood-2019-131148

Published: 2019

Journal Articles

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Milena Mazan, PhD, Marion Chapellier, PhD, Marcus Järås, PhD, Michal Mikula, MD PhD, Eliza Majewska, PhD, Katarzyna Wiklik, PhD, Michal Combik, PhD, Aniela Golas, PhD, Magdalena Masiejczyk, MSc, Elzbieta Fiedor, MSc, Federico Malusa, MSc, Przemyslaw Juszczynski, Prof., MD PhD, Magdalena Cybulska, DVM, Maciej Mikulski, PhD, Jerzy Ostrowski, Prof., MD PhD, Pawel Chrom, MD PhD, Krzysztof Brzózka, PhD, Tomasz Rzymski, PhD

Blood (2019) 134 (Supplement_1): 3774.

https://doi.org/10.1182/blood-2019-128073

Published: 2019

NARROW

A master erythroid regulator gets its own GPS

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

Super-Enhancer Profiling Identifies Novel Oncogenes and Therapeutic Targets in Multiple Myeloma

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

Terminal Erythroid Maturation Is Associated with Dynamic Changes in the Abundance of Histone Marks Associated with Active Transcription Elongation and RNA Polymerase II Pausing

Prevention of Bleeding-Induced Vascular Abnormalities in the Hemophilic Mouse Joint By Increasing TAFI Levels or Inhibiting uPA Activity

Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

LSD1 Inhibitor 4SC-202 Inducing Apoptosis in Myelodysplastic Syndrome Cells Via NF-κb-HO-1 Pathway

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only